Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$107.53 USD
+0.67 (0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $107.69 +0.16 (0.15%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABT 107.53 +0.67(0.63%)
Will ABT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABT
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
ABT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Q1 Earnings Review
Markets Try to Shake Off April Blues
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
Other News for ABT
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
ABT July 19th Options Begin Trading
3 Best Healthcare Stocks to Buy in April 2024, According to Analysts
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Abbott Laboratories stock outperforms competitors despite losses on the day